Skip to main content

Externally anchored fully covered metal stents with plastic stent versus uncovered metal stents for unresectable distal malignant biliary obstruction: a multicenter randomized trial

In brief

Anchored covered biliary stents cut dysfunction from 49% to 27%

In a multicenter randomized trial, stent dysfunction occurred in 27% of patients receiving externally anchored covered stents, versus 49% with uncovered stents; 99 patients were included in the final analysis. Adverse events and overall survival were similar between groups, so the approach may improve drainage durability, but larger studies are needed to confirm the result.

Journal
Endoscopy (Q1)
Published
16 November 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Jin Ho Choi, Junyeol Kim, Woo Hyun Paik, In Rae Cho, Ji Kon Ryu, Sung Yong Han, et al.
PMID
43039341
DOI
10.1055/a-2963-1915

Why clinicians should know about it

  • Picked for Gastroenterology (paper of the day, 17 November 2026): Randomized comparison of endoscopic stents for malignant biliary obstruction

Abstract

BACKGROUND: Self-expandable metal stents (SEMS) are commonly used to treat malignant biliary obstruction (MBO). External plastic stent anchoring for fully covered SEMS (FCSEMS-EPS) has shown potential to improve stent patency; however, randomized evidence comparing this strategy with uncovered SEMS (USEMS) is limited. METHODS: This multicenter trial was conducted at nine tertiary referral centers in South Korea. Patients were enrolled from October 2021 to February 2024 and followed for 12 months after stent placement. Those with unresectable distal MBO were randomly assigned (1:1) to receive either FCSEMS-EPS or USEMS. The primary outcome was biliary stent dysfunction. Time-to-event analyses were performed using time to stent dysfunction within a competing risk framework. RESULTS: 113 patients were enrolled, of whom 99 were included in the final analysis (FCSEMS-EPS 48; USEMS 51). Stent dysfunction occurred less frequently in the FCSEMS-EPS group compared with the USEMS group (27.1% vs. 49.0%; P = 0.04). The cumulative incidence of stent dysfunction at 6 months was lower in the FCSEMS-EPS group (21.1% vs. 29.8%; Gray's test, P = 0.03). In multivariable competing risk analysis, FCSEMS-EPS was independently associated with a lower risk of stent dysfunction (subdistribution hazard ratio 0.44, 95%CI 0.21-0.90; P = 0.03). Procedure-related adverse events and overall survival did not differ between groups. CONCLUSION: FCSEMS-EPS significantly reduced stent dysfunction compared with USEMS without increasing adverse events, supporting its effectiveness and safety as long-term biliary drainage in unresectable MBO.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.